Methylphenidate Viatris Limited (Methylphenidate Hydrochloride)

Methylphenidate works by blocking the reuptake transporters for dopamine and norepinephrine, which raises the levels of these neurotransmitters in the brain. The increased dopaminergic and noradrenergic activity, especially in the prefrontal cortex, enhances attention, alertness, and executive function, providing therapeutic benefit for ADHD and narcolepsy.

The dosage of methylphenidate is individualized and determined by the prescribing clinician based on the patient’s age, weight, severity of symptoms, and response to therapy. The prescriber will select the appropriate strength, formulation, and dosing schedule to achieve optimal clinical effect while minimizing adverse reactions.

Safety data for methylphenidate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Healthcare providers typically advise women to discuss their specific situation with a specialist before starting or continuing therapy while pregnant or nursing.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Methylphenidate belongs to the central nervous system stimulant class and is comparable to amphetamine‑based agents such as mixed amphetamine salts. Both increase dopamine and norepinephrine activity, but methylphenidate primarily blocks reuptake, whereas amphetamines also promote release. Choice of agent depends on individual response, side‑effect profile, and prescriber preference.

Methylphenidate Viatris Limited should be stored at room temperature, below 25 °C (77 °F). Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Methylphenidate is administered orally, typically as a tablet or capsule taken once or multiple times per day, depending on the prescribed formulation. The medication should be swallowed whole with water and taken at the time of day recommended by the prescriber, often in the morning to reduce the risk of insomnia.

Serious risks include cardiovascular events such as hypertension, tachycardia, or arrhythmias, as well as psychiatric effects like psychosis, severe anxiety, or emergence of tics. Rarely, an allergic reaction may occur. Patients should be monitored regularly for these events, and therapy should be discontinued if severe adverse reactions develop.

Methylphenidate is contraindicated in individuals with known hypersensitivity to the drug, those taking monoamine oxidase inhibitors (MAOIs) within the past 14 days, and patients with severe cardiovascular disorders such as uncontrolled hypertension or structural heart disease. It should also be used with caution in patients with a history of psychosis, severe anxiety, or Tourette syndrome.